Development of the novel ant-metastatuc therapy against circulating tumor cells

2014 Fiscal Year Final Research Report

• Project/Area Number: 25670661
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Research Institute, Osaka Medical Center for Cancer and Cardiovascular Disaeses
• Principal Investigator: KAZUYUKI Itoh 地方独立行政法人大阪府立病院機構大阪府立成人病センター(研究所), その他部局等, その他 (20301806)
• Co-Investigator(Renkei-kenkyūsha): YOSHIKAWA Hideki 大阪大学, 医学系研究科, 教授 (60191558)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 転移 / 循環腫瘍細胞 / 骨肉腫 / 血管内皮細胞増殖因子 / 組織の硬さ

Outline of Final Research Achievements

Circulation tumor cells (CTCs) appeared in the early phase of metastasis and the growth of metastasized cells in the target organs are critical during the multistep lung metastasis by musclo-skeletal malignant tumors. We established the method to purify the living CTCs from osteosarcoma (OS) bearing mouse using our previously reported highly metastatic OS cell line LM8. By comparison between CTCs from LM8 and primary tumor cells, we found the higher anti-anokis activity of LM8-derived CTCs. We also found that vascular endothelial growth factor (VEGF) plays an important role of three dimensional growth of OS in soft-stiffness condition mimicking lung, compare to the hard stiffness primary sites. Using the small molecules targeted to the VEGF signal, we confirmed the effective inhibition of OS lung metastasis in vivo syngeneic mouse orthotropic experimental metastasis model.

Free Research Field

腫瘍生物学